Roth Capital Maintains Buy on BioHarvest Sciences, Lowers Price Target to $8

Benzinga Newsdesk www.benzinga.com Neutral 51.9%

Neg 0% Neu 51.9% Pos 0%

Roth Capital analyst Sean McGowan maintains BioHarvest Sciences (NASDAQ:BHST) with a Buy and lowers the price target from $10 to $8.